EU Clinical Trial 2018-002932-26

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)  May 21, 2019

Main objective of the trial: Efficacy - Assess the antitumor activity of durvalumab alone and/or in combination with novel agents Eficacia - Evaluar la actividad antitumoral de durvalumab en monoterapia y/o en combinación con fármacos innovadores

Parties

Sponsors
Countries
CA CH ES FR IT PT US
Keywords
AZD9150 IPH2201 MEDI4736 MEDI9447 Non-small cell lung cancer stage I Non-small cell lung cancer stage II Non-small cell lung cancer stage IIIA danvatirsen durvalumab monalizumab oleclumab

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.